Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T22:43:13.056Z.
Calculation as of: 2026-10-06T22:43:13.056Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 680db3c2305e98602fe5277f15244516f30a0ab53cbf5830e5b41f5092839f7c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$853.13M
EV/Sales Ratio
3.01x
TTM Avg
2.50x
3Y Avg
2.16x
5Y Avg
2.36x
Market Cap
$855.38M
EV/Sales Ratio
111.94x
TTM Avg
171.82x
3Y Avg
125.82x
5Y Avg
125.82x
Market Cap
$857.16M
EV/Sales Ratio
1.42x
TTM Avg
1.51x
3Y Avg
1.76x
5Y Avg
1.99x
Market Cap
$838.62M
EV/Sales Ratio
9.32x
TTM Avg
7.35x
3Y Avg
8.21x
5Y Avg
14.47x
Market Cap
$838.16M
EV/Sales Ratio
6.72x
TTM Avg
7.73x
3Y Avg
8.84x
5Y Avg
8.84x
Market Cap
$870.81M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$833.81M
EV/Sales Ratio
27.21x
TTM Avg
18.85x
3Y Avg
39.02x
5Y Avg
39.02x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SL Science Holding Ltd (SLBT) | $852.35M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 3.01x | 2.50x | 2.16x | 2.36x |
| Alumis Inc. (ALMS)vs › | $855.38M | 111.94x | 171.82x | 125.82x | 125.82x |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | 1.42x | 1.51x | 1.76x | 1.99x |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | 9.32x | 7.35x | 8.21x | 14.47x |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | 6.72x | 7.73x | 8.84x | 8.84x |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | 3.94x | 3.51x | 4.09x | 5.12x |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | 27.21x | 18.85x | 39.02x | 39.02x |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $828.48M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
